Skip to main content
NKMAX Co., Ltd. logo

NKMAX Co., Ltd. — Investor Relations & Filings

Ticker · 182400 ISIN · KR7182400002 KO Manufacturing
Open in API
Filings indexed 501 across all filing types
Latest filing 2023-03-14 AGM Information
Country KR South Korea
Listing KO 182400

About NKMAX Co., Ltd.

https://nkmax.com/

NKMAX Co., Ltd. is a biotechnology company focused on developing immune-based solutions centered on Natural Killer (NK) cells. The company's primary focus is the development of adoptive cell therapies to treat incurable diseases, including cancer, autoimmune disorders, and neurodegenerative conditions. Its portfolio includes anti-cancer immunotherapy treatments and other biological products. In addition to therapeutics, NKMAX develops and markets a precision diagnostic test that measures NK cell activity. The company also manufactures and supplies specialized reagents, such as high-quality recombinant proteins and antibodies, for biotechnology research, as well as a line of health functional foods designed to support the immune system.

Recent filings

Filing Released Lang Actions
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) issued by NKMAX. It outlines the date, location, agenda items (such as financial statement approval and director appointments), and voting procedures. This type of document is a standard proxy solicitation or notice of meeting sent to shareholders to inform them of upcoming voting matters, which falls under the Proxy Solicitation & Information Statement category.
2023-03-14 Korean
주주총회소집공고
AGM Information Classification · 98% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) for NKMAX Co., Ltd. It contains the meeting agenda, voting procedures, and detailed management information (such as director activities and business overviews) required for shareholders to make informed decisions. This aligns with the definition of a Proxy Solicitation & Information Statement (PSI), which provides information and requests votes for meetings.
2023-03-14 Korean
전환가액의조정
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing regarding the adjustment of the conversion price of convertible bonds (CB) for NKMAX. It details the change in conversion price, the number of convertible shares, and the underlying reasons (market price decline). This type of disclosure regarding capital structure changes, specifically related to convertible debt instruments, falls under the 'Capital/Financing Update' category.
2023-03-10 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. This document specifically details changes in share ownership, special relationships, and contractual arrangements (such as stock collateral loans) by major shareholders. This falls under the category of Major Shareholding Notification.
2023-03-03 Korean
투자판단관련주요경영사항(표준요법에 실패한 전이 또는 국소적으로 진행된 고형암 환자를 대상으로 SNK02 정맥 투여의 내약성,안전성 평가 및 항종양 효과 탐색을 위한 공개,용량대조,3+3 설계,용량증량,다기관,1상 임상시험 계획 변경 신청)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from a Korean company (NKMAX) regarding a 'Major Management Matter' (투자판단 관련 주요경영사항), specifically the submission of an application to change a Phase 1 clinical trial plan for a cancer treatment (SNK02). This type of disclosure is a standard regulatory announcement for material corporate events in the Korean market. Since it does not fit into specific categories like financial reports, dividends, or M&A, and is a formal regulatory disclosure, it is classified as a Regulatory Filing (RNS).
2023-03-03 Korean
전환가액의조정
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing regarding the adjustment of the conversion price of convertible bonds (전환가액의 조정). This type of disclosure relates to changes in the company's capital structure and financial instruments. Since it specifically details the adjustment of conversion prices for outstanding convertible bonds, it falls under the category of Capital/Financing Update (CAP).
2023-03-02 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.